- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Crisis Management
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
Brian A. Bohnenkamp
Insights 17 results
Client Alert
April 25, 2022
COVID-19 Health Care Fraud Enforcement on the Rise: What’s Ahead for the Life Sciences & Healthcare Industries
Client Alert
March 28, 2022
AdvaMed Updates Code of Ethics on Interactions with HCPs: What’s the Impact on MedTech?
Client Alert
August 17, 2021
Revised PhRMA Code Provides Stricter Controls on HCP Speaker Programs
Client Alert
February 3, 2021
Implementation of Final Rule Excluding PBM Rebates from Discount Safe Harbor Delayed Until 2023
Feature
January 15, 2021
General Counsel Internal Investigations Decision Tree for the Life Sciences Industry
Client Alert
November 25, 2020
HHS Finalizes Rule Challenging Drug Manufacturer Rebates to PBMs and Payors
Client Alert
November 24, 2020
Are Pharma Speaker Programs Facing an Existential Crisis?
Client Alert
October 17, 2019
HHS Issues Proposed Rule to Update Anti-Kickback Statute Safe Harbors – What Does it Mean for Life Sciences Companies?
Article · Source: Health Care Compliance Professional’s Manual
Client Alert
April 21, 2017
New York Institutes New Medicaid Drug Price Control Measures
Client Alert
December 14, 2016
OIG Issues Final Rule Expanding Anti-Kickback Statute Safe Harbors and Revising Civil Monetary Penalty Regulations
Client Alert
August 25, 2015
OIG Issues Advisory Opinion Regarding Pharmaceutical Manufacturer Free Drug Program